SNORD82 as A Potential Drug Target for Cancer Treatment (G25826)

Target Name: SNORD82

NCBI ID: G25826

SNORD82

Other Name(s): Z25 | U82 | Small nucleolar RNA, C/D box 82 | RNU82 | small nucleolar RNA, C/D box 82

SNORD82 as A Potential Drug Target for Cancer Treatment

SNORD82 (Z25) is a protein that is expressed in various tissues and organs, including the brain, heart, lungs, and kidneys. It is a key regulator of the cell cycle, and is involved in the development and progression of many diseases, including cancer.

Recent studies have identified SNORD82 as a potential drug target (or biomarker) for the treatment of various diseases, including cancer. One of the main reasons for its potential as a drug target is its involvement in the regulation of the cell cycle. SNORD82 is a key regulator of the G1/S transition, which is a critical step in the cell cycle that leads to the completion of DNA replication and the start of cell division.

Studies have shown that SNORD82 plays a key role in the regulation of the cell cycle by controlling the amount of chromatin that is accessible to the transcription factors that are responsible for regulating gene expression. This means that when SNORD82 is activated, it causes the chromatin to become more compact and less accessible to transcription factors, which can lead to the repression of gene expression.

In addition to its role in the cell cycle, SNORD82 has also been shown to be involved in the regulation of cell survival and the development of cancer. Many studies have shown that SNORD82 is highly expressed in cancer cells, and that it is involved in the development of various types of cancer, including breast, ovarian, and prostate cancer.

Furthermore, SNORD82 is also involved in the regulation of the blood-brain barrier, which is a barrier that separates the brain from the rest of the body. The blood-brain barrier is designed to protect the brain from harmful substances, but it can also allow certain substances to enter the brain. Studies have shown that SNORD82 plays a key role in the regulation of the blood-brain barrier, and that it is involved in the development of various neurological disorders, including Alzheimer's disease.

In conclusion, SNORD82 is a protein that is involved in the regulation of the cell cycle, cell survival, and the development of cancer. As a result, it is a potential drug target (or biomarker) for the treatment of various diseases, including cancer. Further studies are needed to fully understand the role of SNORD82 in these processes and to develop effective treatments.

Protein Name: Small Nucleolar RNA, C/D Box 82

The "SNORD82 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD82 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets